Marcia Fournier United States

BIOARRAY is a biotech company located at the Science park in New Haven. BIOARRAY is customizing treatments for patients to cure breast cancer the first time. BIOARRAY’s lead breast cancer test has been shown to reduce ineffective treatments by over 50% in proof of concept studies. BIOARRAY is a recipient of Avon Foundation and Connecticut Innovations funds. BIOARRAY is a MassChallenge Accelerator Winner.

Biotech Subsector
Biotech Phase of Development
Technology Overview

In contrast to most studies that focus on the unhealthy cancer patient populations, BIOARRAY studies cancer in reverse by using genes in healthy cell organization to identify cancer markers. These biomarkers work like surveillance cameras watching how a particular breast cancer will behave when treated with chemotherapy. By measuring the mRNA expression levels of these biomarkers, Bioarray diagnostic tests significantly increase the accuracy of predicted chemo-response rates.

Alliance & Collaborations
Avon Foundation, Connecticut Innovations
Supporting Metrics or Evidence

BIOARRAY's lead test distinguishes itself by addressing a vital question at the beginning of basic chemotherapeutic treatment for 75% of diagnosed breast cancer patients who currently have a 24% response rate. BIOARRAY's test clinical proof of concept studies showed:

55% reduction in ineffective chemo

68% improvement in response rate

42% of patients classified as non-responders up front

Current Financing Needs

The company is raising its Series A round of financing to achieve key milestones to take the lead test to early adoption.

Current Timeline

BIOARRAY has developed a business plan whereas the Bioarray diagnostic uses commercially-available gene-expression platforms such as PCR for its lab analysis. BIOARRAY will engage licensees and distributors to access the global market. BIOARRAY will hold closely the proprietary algorithms at the heart of the diagnostic in a cloud-based information platform. BIOARRAY's lead test is in a position to go to market within 2 years.

Current Investors

Grant: Avon Foundation – first of its kind from Avon

Equity: Connecticut Innovations and Angels

IP Status

BIOARRAY intellectual property includes methods, algorithms and biomarkers. BIOARRAY strategy to protect its intellectual property is a combination of trade secrets and patents. The company is growing a patent portfolio of US and international patents that is exclusively owned by BIOARRAY and is not subject to licensing or royalty obligations.

Recent Milestones

  1. Performed clinical proof of concept with I-SPY 1 clinical trial
  2. Data gathered (and ready to complete analysis) for I-SPY 2 trial
  3. Built cloud-based interactive information platform and interactive portal
  4. Built laboratory infrastructure
  5. Developed IP strategy comprising know-how and patents (internationally filed)
Management Team Highlights

CEO Marcia Fournier has over a decade of experience in oncology at leading Institutions in the US. Non-executive chairman Michal Preminger and Board Directors Una Ryan and Henry Kay have extensive experience in management, financing, acquisitions, and diagnostics. The Company also has a team of active business advisors with experience in business development, acquisitions and venture capital.

Marcia Fournier
Bioarray Therapeutics Inc.
LinkedIn logo CEO 
BIO

Marcia, a molecular biologist, came to the United States from Brazil about 15 years ago. Marcia is trained in genetics with 10+ years of experience in cancer research. She most recently held a position at GlaxoSmithKline, Oncology Center of Excellence for Drug Discovery. Marcia’s work as a doctoral fellow at the Dana-Farber Institute and postdoctoral fellow at UC Berkeley led to seminal publications on biomarker discovery.

Sara Frankel

Astia is an organization whose mission is to provide women-led startups access to capital resources and executive leadership. Astia was founded in 2013 and is based in San Francisco California with additional offices in New York New York and London United Kingdom. Astia typically provides access to capital to women-led life science companies through two programs: Astia Venture Lunches and Astia Angels and is in the process of developing a third program: Astia Fund. Companies that apply to Astia Venture Lunches will be vetted by Astia?s Expert Sift process. The selected companies are invited to present to a room of accredited investors: VCs and angels. Companies applying to Astia are also considered by Astia Angels and the investments from Astia Angels are typically under $1 million. Astia is stage agnostic though companies applying should be able to show traction and proof of concept. Companies can be global and must have at least one woman in a leadership position of significant influence and holding equity.
Astia Angels
Member 

Dr Patrik Frei Switzerland

Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Further more, the company runs the global Biotech Database (www.biotechgate.com) as a subscription service as well as a white label solution for clients like BIOTECanada, BioCom San Diego, Maryland, HTX, OneNucleus, Swiss Biotech Association, SwedenBIO, Medicon Valley and many more.

Company Valuation:
----------------------------
The Company Valuation Reports include a thorough assessment of the company by experienced professionals with expertise in the relevant fields as well as the following elements:

  • summary of key risk parameters and strengths of the company
  • outline of the crucial factors and value drivers for growth and further strategic development
  • assessment of the management, market, science, technology and products
  • analysis of the company’s business model and the company’s competitive environment
  • detailed calculation of the company’s financial value, using appropriate valuation methods


Product Valuation:
--------------------------
Venture Valuation offers detailed Product Valuation Reports of pre-clinical and clinical products in development that can serve as a basis for negotiations or to structure different deal scenarios. The Product Valuation includes:

  • detailed analysis of development costs, time lines, patient population, competing products, pricing and product life cycle
  • industry gold standard rNPV valuation methodology based on indication-specific attrition rates and the development stage
  • scenario and sensitivity analyses
  • analysis of the current value, and forecasts of the future value following the successful completion of key development milestones


As an “add on” module and based on Venture Valuation’s deal database within Biotechgate, benchmarking deals can also be included to provide the client with a differentiated negotiation basis and comparable information.

Licensing Candidate Search:
----------------------------------------
Based on unique valuation and industry expertise, and leveraging access to the proprietary client and products database, Venture Valuation offers individual, tailor-made solutions to customers. The Licensing Candidate Search includes licensing partner identification and an evaluation of potential products for licensing.

Biotechgate Database:
-------------------------------
Venture Valuation has developed and maintains the Biotechgate Database (biotechgate.com). Biotechgate is a global life sciences directory established in 2004 based on the needs of investors and company managers to access accurate and up-to-date industry intelligence.

The database contains over 30’000 company profiles. For Business Development managers, the database provides benchmarking licensing opportunities as well as detailed financial information covering more than 1’600 licensing deals involving therapeutic products and over 5’000 financing rounds.

Dr Patrik Frei
Venture Valuation
CEO 

Peter French Australia

BCAL Diagnostics is a Sydney, Australia based blood diagnostics company with research facilities based in Kentucky, USA.

The BCAL lipid biomarker test is a universal blood test for the effective screening and monitoring of breast cancer.  The BCAL test is being developed to be safe, cost effective, accurate and available to all women regardless of age, race and geographic location.

BCAL Diagnostics is near completion of a 200-patient study. Initial results indicate the BCAL test has a greater than 90% sensitivity and specificity in the diagnosis of invasive ductal carcinoma which is 85% of all breast cancers. 

This will lead to a range of BCAL breast cancer blood tests that can be used across the full breast cancer disease management continuum. from pre-disposition to screening to long term monitoring.

BCAL Diagnostics is now seeking Series B capital of $5-$10M USD to support its global commercialisation activities.

Year Founded
2010
Biotech Subsector
Medtech Subsector
Medtech Phase of Development
Technology Overview
Breast Cancer Associated Lipids
Alliance & Collaborations
Research agreements with Kentucky University USA and Royal Prince Alfred Hospital - NSW Australia
Supporting Metrics or Evidence
80 patient study completed - 200 patient study near completion
Current Financing Needs
$5-$10M Series B
Current Investors
small number of highly sophisticated investors
IP Status
Strong - patents pending
Recent Milestones
Completed 100 sample study with 90% sensitivity and specificity results for the detection of invasive ductal carcinoma
Management Team Highlights
CEO has global diagnostic experience with Roche Diagnostics, Boehringer Mannheim and Cochlear. Management team has extensive lipids in cancer experience with published papers and PhD
BCAL Diagnostics Pty Ltd
Director & Scientific Advisor 

Brian Frenzel

The Band of Angels is a funding organization that was founded in 1994 and it is based in Silicon Valley California. The organization typically provides capital to companies through three programs: The Band of Angels Acorn Fund and The Band of Angels Venture Fund. The group focuses on seed and Series A stage high-tech companies across several industries including life science space. The Band of Angels generally makes investments ranging from $3K to $75k but it often leads a syndication of $2-3million. Acorn Fund which is The Band?s third side fund and was founded in 29 generally makes investments ranging from $1k to $75k. The Band of Angels Venture Fund is a $5 million venture fund which raised in 1999 by The Band of Angels. Initial investment sizes of the fund are typically $3 and can go up to $2.5 million. The Band generally makes around 1 -2 investments per year. The group focuses on companies based in Silicon Valley but it will consider selective opportunities in Los Angles and San Diego areas. The group's portfolio includes biotechnology and medical device companies working with oncology and muscle recovery.
Band of Angels
Member 

Jack Fuller

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient. 

Biotech Phase of Development
Medtech Phase of Development
Unique Capabilities

Life Science Investor Profiles, LSN has sourced validated and maintains the largest global database of investor profiles. LSN defined 10 categories of Life Science Investor;

·         Private Equity

·         Venture capital

·         Family Offices

·         Corporate VC

·         Angel Groups

·         Large Pharma/ Biotech

·         Alternative Institutional Investors: Pensions, Endowments

·         Endowments/Foundations

·         Hedge Funds

·         Government Grants

Marketing Services, LSN consults on branding, messaging, and outbound marketing strategies. This includes developing a tagline, elevator pitch, executive summary, corporate power point presentation, and new or updated website design to fit your brand and message. LSN will develop a Global Target List of prequalified candidates to target for marketing initiatives.

Life Science Nation